Comment on

“Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”

Georgios Tsivgoulis, Lina Palaiodimou, Aristeidis H. Katsanos, Konstantinos Voumvourakis, Georgios M. Hadjigeorgiou, Ioannis Heliopoulos, Theodore Karapanayiotides, Panagiotis Papathanasopoulos, Constantinos Kilidireas, Nikolaos Grigoriadis

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)293-295
Number of pages3
JournalCNS Drugs
Volume33
Issue number3
DOIs
StatePublished - Mar 6 2019

Fingerprint

Mouth Diseases
Multiple Sclerosis

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Comment on : “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”. / Tsivgoulis, Georgios; Palaiodimou, Lina; Katsanos, Aristeidis H.; Voumvourakis, Konstantinos; Hadjigeorgiou, Georgios M.; Heliopoulos, Ioannis; Karapanayiotides, Theodore; Papathanasopoulos, Panagiotis; Kilidireas, Constantinos; Grigoriadis, Nikolaos.

In: CNS Drugs, Vol. 33, No. 3, 06.03.2019, p. 293-295.

Research output: Contribution to journalLetter

Tsivgoulis, G, Palaiodimou, L, Katsanos, AH, Voumvourakis, K, Hadjigeorgiou, GM, Heliopoulos, I, Karapanayiotides, T, Papathanasopoulos, P, Kilidireas, C & Grigoriadis, N 2019, 'Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”', CNS Drugs, vol. 33, no. 3, pp. 293-295. https://doi.org/10.1007/s40263-019-00615-5
Tsivgoulis, Georgios ; Palaiodimou, Lina ; Katsanos, Aristeidis H. ; Voumvourakis, Konstantinos ; Hadjigeorgiou, Georgios M. ; Heliopoulos, Ioannis ; Karapanayiotides, Theodore ; Papathanasopoulos, Panagiotis ; Kilidireas, Constantinos ; Grigoriadis, Nikolaos. / Comment on : “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”. In: CNS Drugs. 2019 ; Vol. 33, No. 3. pp. 293-295.
@article{31ac62dd64ad4c9d8f7fec23093f04c5,
title = "Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”",
author = "Georgios Tsivgoulis and Lina Palaiodimou and Katsanos, {Aristeidis H.} and Konstantinos Voumvourakis and Hadjigeorgiou, {Georgios M.} and Ioannis Heliopoulos and Theodore Karapanayiotides and Panagiotis Papathanasopoulos and Constantinos Kilidireas and Nikolaos Grigoriadis",
year = "2019",
month = "3",
day = "6",
doi = "10.1007/s40263-019-00615-5",
language = "English (US)",
volume = "33",
pages = "293--295",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Comment on

T2 - “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”

AU - Tsivgoulis, Georgios

AU - Palaiodimou, Lina

AU - Katsanos, Aristeidis H.

AU - Voumvourakis, Konstantinos

AU - Hadjigeorgiou, Georgios M.

AU - Heliopoulos, Ioannis

AU - Karapanayiotides, Theodore

AU - Papathanasopoulos, Panagiotis

AU - Kilidireas, Constantinos

AU - Grigoriadis, Nikolaos

PY - 2019/3/6

Y1 - 2019/3/6

UR - http://www.scopus.com/inward/record.url?scp=85062606409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062606409&partnerID=8YFLogxK

U2 - 10.1007/s40263-019-00615-5

DO - 10.1007/s40263-019-00615-5

M3 - Letter

VL - 33

SP - 293

EP - 295

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 3

ER -